Gyre Therapeutics, Inc. Dilutive Share Adjustment
Gyre Therapeutics, Inc. (GYRE) reported Dilutive Share Adjustment of 261.40 thousand shares for the 9-month period ending 2012-09-30, per its 10-Q filed 2013-11-06.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment · last filed 2013-11-06
- Gyre Therapeutics, Inc. weighted average number diluted shares outstanding adjustment for the quarter ending 2012-09-30 was 180.12K shares.
- Gyre Therapeutics, Inc. weighted average number diluted shares outstanding adjustment for the quarter ending 2012-06-30 was 229.29K shares.
- Gyre Therapeutics, Inc. weighted average number diluted shares outstanding adjustment for the quarter ending 2012-03-31 was 431.72K shares.
- Gyre Therapeutics, Inc. weighted average number diluted shares outstanding adjustment for fiscal 2010 was 1.61M shares.
| Period end | Weighted Average Number Diluted Shares Outstanding Adjustment 3 month | Weighted Average Number Diluted Shares Outstanding Adjustment 6 month | Weighted Average Number Diluted Shares Outstanding Adjustment 9 month | Weighted Average Number Diluted Shares Outstanding Adjustment 12 month |
|---|---|---|---|---|
| 2012-09-30 | 180.12K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | 204.70K shares derived: average of 2 quarters · filed 2013-11-06 | 261.40K shares 10-Q · filed 2013-11-06 | |
| 2012-06-30 | 229.29K shares 10-Q · filed 2013-08-07 | 302.04K shares 10-Q · filed 2013-08-07 | ||
| 2012-03-31 | 431.72K shares 10-Q · filed 2013-05-08 | |||
| 2011-09-30 | 1.31M shares 10-Q · filed 2012-11-08 | |||
| 2010-12-31 | 1.61M shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |